Skip to content

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

Observational Study for the Assessment of Bone Mineral Density (BMD) Using REMS Technology

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07412782
Enrollment
100
Registered
2026-02-17
Start date
2025-12-04
Completion date
2026-12-31
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Deficiency (GHD), Hypercortisolism, Hypogonadisms, Malnutrition (Calorie), Neoplasia, Obesity & Overweight, Osteogenesis Imperfecta, Osteopenia, Osteoporosis

Brief summary

This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free ultrasound technology. Bone health is crucial during childhood, when peak bone mass develops, and reduced BMD is associated with increased fracture risk. DXA is the current reference method but has limitations in children, including radiation exposure and growth-related measurement issues. REMS has been validated in adults and shows promise in pediatrics, despite the lack of reference values. The study is a single-center, national, non-profit interventional study lasting about 12 months. Participants will undergo REMS BMD measurement, clinical history collection, and assessment of anthropometric and pubertal parameters, with prior DXA data collected when available. The primary aim is to describe BMD values measured by REMS in pediatric osteoporosis, with secondary aims including subgroup analyses and comparison with DXA. A sample of 100 patients is planned. Statistical analyses will assess BMD distributions, correlations with clinical variables, and agreement between REMS and DXA using correlation coefficients and Bland-Altman analysis.

Interventions

DIAGNOSTIC_TESTREMS

REMS (Radiofrequency Echographic Multi Spectrometry) technology, a non-invasive, radiation-free ultrasound system to detect BMD. REMS has obtained FDA and CE approval and has been validated

Sponsors

Meyer Children's Hospital IRCCS
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Written informed consent from adult patients or parents/legal guardians * Age between 5 and 18 years * Both sexes and all ethnicities * Known condition negatively affecting bone health

Exclusion criteria

\- Age below 5 years or over 18 years

Design outcomes

Primary

MeasureTime frameDescription
BMD values in primary osteoporosisAt the enrollementMean and median of Bone Mineral Density values obtained in the pediatric population affected by primary osteoporosis

Secondary

MeasureTime frameDescription
BMD values in pediatric patients with conditions negatively affecting bone healthAt the enrollementMean and median of Bone Mineral Density values in pediatric patients with conditions negatively affecting bone health

Countries

Italy

Contacts

CONTACTStefano Stagi, Professor
stefano.stagi@unifi.it0039 0555662305

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026